Article

Sequential ATR and PARP Inhibition Overcomes Acquired DNA Damaging Agent Resistance in Pancreatic Ductal Adenocarcinoma

2024-09-13

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) remains the most lethal cancer and will soon be the second most common cause of cancer related death. While regimens containing DNA damaging agents such as FOLFIRINOX and PARP inhibitors have derived clinical benefits for some patients, their efficacy invariably fails over time. This presents a significant clinical challenge, and thus there is an urgent need for novel therap...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8aa59234-ca4f-5855-bd4c-8ba7137dcb3a
DOI: 10.1101/2024.09.09.609499

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sequential ATR and PARP Inhibition Overcomes Acquired DNA Damaging Agent Resistance in Pancreatic Ductal AdenocarcinomaDOI 10.1101/2024.09.09.609499Read

Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinomaSemantic proximity Read

Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.Semantic proximity Read

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.Semantic proximity Read

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53Semantic proximity Read

Targeting BRCA and PALB2 in Pancreatic Cancer.Semantic proximity Read

BRCA mutations in pancreatic cancer and progress in their targeting.Semantic proximity Read

The Landscape of Pancreatic Cancer Therapeutic Resistance MechanismsSemantic proximity Read

Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.Semantic proximity Read

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsSemantic proximity Read

Targeting DNA Damage Response and Replication Stress in Pancreatic CancerSemantic proximity Read

Challenges of drug resistance in the management of pancreatic cancerSemantic proximity Read

Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent TumorsSemantic proximity Read